§522.313

wounds) in dogs caused by susceptible strains of *Staphylococcus intermedius* and *Streptococcus canis* (Group G).

- (2) Cats—(i) Amount. Administer 3.6 mg/lb (8 mg/kg) body weight as a single, one-time subcutaneous injection.
- (ii) *Indications for use*. For the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of *Pasteurella multocida*.

[73 FR 29685, May 22, 2008]

§ 522.313 Ceftiofur injectable dosage forms.

§ 522.313a Ceftiofur crystalline free acid.

- (a) Specifications. The product is a suspension of ceftiofur crystalline free acid.
- (1) Each milliliter (mL) contains 100 milligrams (mg) ceftiofur equivalents.
- (2) Each mL contains 200 mg ceftiofur equivalents.
- (b) *Sponsor*. See No. 000009 in §510.600(c) of this chapter.
- (c) Related tolerances. See §556.113 of this chapter.
- (d) Special considerations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
- (e) Conditions of use—(1) Swine. The formulation described in paragraph (a)(1) of this section is used as follows:
- (i) Amount. 5.0 mg CE per kilogram (kg) of body weight by intramuscular injection in the postauricular region of the neck.
- (ii) Indications for use. For the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis, and Streptococcus suis. For the control of SRD associated with A. pleuropneumoniae, P. multocida, H. parasuis, and S. suis in groups of pigs where SRD has been diagnosed.
- (iii) Limitations. Following label use as a single treatment, a 14-day preslaughter withdrawal period is required.
- (2) Cattle. The formulation described in paragraph (a)(2) of this section is used as follows:
- (i) Amount. 6.6 mg ceftiofur equivalents per kg of body weight as a single injection. For subcutaneous injection in the middle third of the posterior aspect of the ear or in the posterior as

pect of the ear where it attaches to the head (base of the ear) in beef and non-lactating dairy cattle. For subcutaneous injection in the posterior aspect of the ear where it attaches to the head (base of the ear) in lactating dairy cattle.

- (ii) Indications for use. For the treatment of bovine respiratory disease (BRD, shipping fever, pneumonia) associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni in beef, non-lactating dairy, and lactating dairy cattle. For the control of respiratory disease in beef and nonlactating dairy cattle which are at high risk of developing BRD associated with M. haemolytica, P. multocida, and H. somni. For the treatment of bovine foot rot (interdigital necrobacillosis) associated with Fusobacteriumnecrophorum and Porphyromonas levii in beef, non-lactating dairy, and lactating dairy cattle.
- (iii) Limitations. Following label use as a single treatment, a 13-day preslaughter withdrawal period is required. A withdrawal period has not been established in preruminating calves. Do not use in calves to be processed for yeal.
- (3) *Horses*. The formulation described in paragraph (a)(2) of this section is used as follows:
- (i) *Amount*. Two intramuscular injections, 4 days apart, at a dose of 3.0 mg/lb (6.6 mg/kg) body weight.
- (ii) Indications for use. For the treatment of lower respiratory tract infections in horses caused by susceptible strains of Streptococcus equi ssp. zooepidemicus.
- (iii) *Limitations*. Do not use in horses intended for human consumption.

[68 FR 60296, Oct. 22, 2003, as amended at 69 FR 43892, July 23, 2004. Redesignated and amended at 71 FR 39546, July 13, 2006; 73 FR 58872, Oct. 8, 2008; 75 FR 4692, Jan. 29, 2010; 75 FR 62468, Oct. 12, 2010]

§522.313b Ceftiofur hydrochloride.

- (a) Specifications. Each milliliter of ceftiofur hydrochloride suspension contains 50 milligrams (mg) ceftiofur equivalents.
- (b) *Sponsor*. See No. 000009 in §510.600(c) of this chapter.
- (c) Related tolerances. See §556.113 of this chapter.